Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) EBIT Margin (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed EBIT Margin for 12 consecutive years, with 0.09% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 1014.0% year-over-year to 0.09%, compared with a TTM value of 1.64% through Dec 2025, up 635.0%, and an annual FY2025 reading of 1.64%, up 635.0% over the prior year.
  • EBIT Margin was 0.09% for Q4 2025 at Heron Therapeutics, up from 10.71% in the prior quarter.
  • Across five years, EBIT Margin topped out at 10.23% in Q4 2024 and bottomed at 269.43% in Q2 2021.
  • Average EBIT Margin over 5 years is 104.04%, with a median of 73.55% recorded in 2022.
  • The sharpest move saw EBIT Margin plummeted -5272bps in 2021, then soared 19141bps in 2022.
  • Year by year, EBIT Margin stood at 259.2% in 2021, then surged by 74bps to 67.79% in 2022, then surged by 56bps to 29.85% in 2023, then skyrocketed by 134bps to 10.23% in 2024, then plummeted by -99bps to 0.09% in 2025.
  • Business Quant data shows EBIT Margin for HRTX at 0.09% in Q4 2025, 10.71% in Q3 2025, and 4.4% in Q2 2025.